QuidelOrtho (QDEL) Valuation in Focus After FDA Nod for Transfusion Medicine Innovation

QuidelOrtho (QDEL) recently received FDA approval for its MTS DAT Card, rounding out its gel-based direct antiglobulin testing solution. With this milestone, the company is preparing to display its full transfusion medicine portfolio at an industry event. This move spotlights continued innovation in clinical diagnostics.

See our latest analysis for QuidelOrtho.

QuidelOrtho’s recent FDA approval for the MTS DAT Card seems to have bolstered optimism among investors, with the share price climbing over 4% in the last day alone. Despite momentum around its transfusion medicine portfolio and ongoing product showcases, it has been a rough stretch, as year-to-date the share price return sits at -36.9% and the one-year total shareholder return is down nearly 29%. That said, the past 90 days have brought an encouraging 11.7% share price rebound, suggesting some renewed interest in the stock’s potential.

If the company’s latest innovation has you rethinking the healthcare sector, it is a great time to explore See the full list for free.

These recent moves have sparked debate about QuidelOrtho’s valuation. Investors are now wondering if the recent rebound signals an attractive entry point or if the market has already priced in its future growth trajectory.

Most Popular Narrative: 29.5% Undervalued

QuidelOrtho’s most widely followed narrative assigns a fair value of $40.33, well above the last close of $28.42. This suggests that analysts are pricing in significant upside. The current market price reflects skepticism around rapid improvement, while this narrative sets a much higher bar for what the company must deliver in the coming years.

Expansion into international markets such as Latin America, Asia Pacific, and underpenetrated regions like China, where differentiated technology, low market share, and a large runway for immunoassay growth exist, positions QuidelOrtho to capture increased demand stemming from global health system focus on early detection and public health surveillance. This should drive topline revenue growth. Acquisition of LEX Diagnostics and the planned commercialization of its rapid molecular point-of-care platform addresses the trend toward fast, decentralized testing and is likely to increase recurring revenues and enhance margins as high-value, high-velocity diagnostic solutions become more prevalent.

Read the complete narrative.

Want to know why analysts think QuidelOrtho’s value could surge from here? The magic lies in big bets on rapid earnings growth, expanding margins, and a profit turnaround that may surprise many. Discover the bold numbers and ambitious assumptions driving this eye-catching fair value.

Result: Fair Value of $40.33 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent declines in COVID-related revenues and challenges from discontinued product lines could still threaten QuidelOrtho’s path to sustainable earnings growth.

Find out about the key risks to this QuidelOrtho narrative.

Build Your Own QuidelOrtho Narrative

If you would rather see the numbers for yourself or take a different approach to the story, you can shape your own view in just a few minutes with Do it your way.

A great starting point for your QuidelOrtho research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Smart investing means spotting tomorrow’s winners today. Don’t wait to build your edge when you could find overlooked companies, stable earners, or the next tech legend right now.

• Uncover hidden bargains trading below their true worth with these 874 undervalued stocks based on cash flows. This approach positions your portfolio for potential upside before the broader market catches on.
• Secure steady returns by tapping into generous yield opportunities through these 20 dividend stocks with yields > 3%. This is ideal for those who value reliable payouts and financial resilience.
• Ride the wave of artificial intelligence innovation and pinpoint the standouts set to shape tomorrow’s industries by starting with these 24 AI penny stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com